NNC 079202

Drug Profile

NNC 079202

Alternative Names: FG 9202; NBQX

Latest Information Update: 05 Nov 1997

Price : $50

At a glance

  • Originator Novo Nordisk
  • Class Anti-ischaemics; Antiepileptic drugs; Neuroprotectants
  • Mechanism of Action AMPA receptor antagonists; Glutamate receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Epilepsy; Parkinson's disease

Most Recent Events

  • 05 Nov 1997 Discontinued-Preclinical for Parkinson's disease in USA (Unknown route)
  • 13 Nov 1995 Discontinued-Preclinical for Stroke in United Kingdom (Unknown route)
  • 13 Nov 1995 Discontinued-Preclinical for Stroke in Denmark (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top